Skip to main content

Table 1 Main characteristics of 553 patients treated with atovaquone-proguanil for imported uncomplicated malaria

From: Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases

Male: female ratio

1.9

Median age in years

38.3 (12–79)

Median weight (kg)

74 (40–109)

Continent of birth N (%)

Europe

51 (9.2)

French West Indies

4 (0.7)

Africa

490 (88.6)

Others

8 (1.5)

Previous history of malaria

264/492* (53.7)

HIV positive

21/478* (4.4)

Pre-travel visit

267 (48.3)

Travel clinic

74 (27.7)

Family doctor

113 (42.3)

Unknown

80 (30.0)

Chemoprophylaxis

222 (40.1)

Chloroquine

30 (13.5)

Chloroquine-proguanil

142 (64)

Mefloquine

24 (10.8)

Atovaquone-proguanil

1 (0.4)

Doxycycline

13 (5.9)

Proguanil

10 (4.5)

Unknown

2 (0.9)

Compliance to chemoprophylaxis

50/222* (22.5)

Non-medical prophylaxis

Air-conditionning only

1 (0.2)

Insecticides only

5 (0.9)

Unimpregnated bed net only

11 (2)

Impregnated bed net only

23 (4.1)

Repellents only

23 (4.1)

Impregnated bed net and repellents

12 (2.2)

No prophylaxis

400 (72.4)

Unknown

78 (14.1)

Place of contamination

West Africa

342 (61.8)

Central Africa

148 (26.8)

Madagascar and Comoros

51 (9.2)

East Africa

5 (0.9)

Asia

3 (0.5)

Angola and South Africa

2 (0.4)

Haïti and French Guyana

2 (0.4)

Type of travel

Backpackers

33 (6.0)

Hostel

11 (2.0)

Visiting friends and relatives

431 (77.9)

Unknown

78 (14.1)

  1. *: number of patients with available data.